Metraipolis › archive › dc_1c9705ce818e

Bridging BET bromodomain and immune checkpoint inhibitors through generative bioorganic frameworks for next-generation cancer immunotherapy — Europe PMC PMID:42787872

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42787872
DOI
10.1039/d6md00450d
License (as archived)
solo-consultazione
Archived
2026-10-07T22:25:56.521Z
SHA-256 of the archived text
e9b2dce7ab2534e38d7b51b1707fcff836997c2d069a30fa834d659c8ed855ef
Stable URL of this page
https://metraipolis.com/documento/dc_1c9705ce818e

How to cite

Bridging BET bromodomain and immune checkpoint inhibitors through generative bioorganic frameworks for next-generation cancer immunotherapy — Europe PMC PMID:42787872 — Europe PMC (en), https://europepmc.org/article/MED/42787872 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_1c9705ce818e (Metraipolis archive dc_1c9705ce818e, sha256 e9b2dce7ab2534e38d7b51b1707fcff836997c2d069a30fa834d659c8ed855ef)
BibTeX
@misc{dc1c9705ce818e,
  title = {Bridging BET bromodomain and immune checkpoint inhibitors through generative bioorganic frameworks for next-generation cancer immunotherapy — Europe PMC PMID:42787872},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42787872},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_1c9705ce818e; sha256 e9b2dce7ab2534e38d7b51b1707fcff836997c2d069a30fa834d659c8ed855ef},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42787872. Agents can read the archived copy with the MCP tool read_document.